1. Introduction {#sec0005}
===============

Sweetpotato (*Ipomoea batatas* L.) roots are not only used for human consumption, they are used to make starch materials, processed foods, and distilled spirits in Japan. Starch use accounts for about 15% (131,500 tons) of total sweetpotato production. Starch residues are discharged during starch production and are mainly used in animal feed and compost. Large amounts of the wastewater, which can cause serious environmental problems, are discarded after clarification. Investigation into the uses of the by-products of the sweetpotato starch industry would benefit both the environment and industry.

Sweetpotato has a high nutritional value and phytochemical composition ([@bib0065]). Proteins, sugars, polyphenols and water-soluble polysaccharides derived from sweetpotato are discharged into the wastewater. Water-soluble polysaccharides from sweetpotato are reported to possess immunostimulatory activity ([@bib0150]). A sweetpotato protein was previously shown to have a high amino acid score and anti-diabetic effects ([@bib0030]). In addition, we previously prepared a sweetpotato protein digest (sweetpotato peptide, SPP) with angiotensin I-converting enzyme (ACE) inhibitory activity and demonstrated its hypotensive effects in spontaneously hypertensive rats (SHR) ([@bib0035]). Peptides isolated from food proteins have shown various health benefits, such as antioxidation ([@bib0145]), amelioration of glucose tolerance ([@bib0080]), inhibition of HIV protease ([@bib0140]) and hypocholesterolemic effects ([@bib0050]), as well as hypotensive effects ([@bib0020]). Investigation of SPP will provide valuable data on any health benefits.

In this study, we investigated the effects of SPP on weight gain, lipid accumulation and hyperlipidemia; the profile of serum cholesterol and triglyceride in sub-fractionated lipoprotein; serum leptin and adiponectin levels; and the expression levels of obesity related biomarkers, such as adipocytokine and anorexigenic peptides in the livers of high-fat diet-administered mice.

2. Materials and methods {#sec0010}
========================

2.1. Materials {#sec0015}
--------------

Three proteases were kindly donated by Daiwa Kasei K.K. (Hyogo, Japan) and Amano Enzyme Inc. (Aichi, Japan).

2.2. Preparation of a sweetpotato peptide (SPP) {#sec0020}
-----------------------------------------------

SPP was prepared as previously described ([@bib0035]) with slight modification: sweetpotato roots (cv. Shiroyutaka for starch production, 240 kg) were squeezed, without the addition of water, by an attritor fitted with a centrifugal dehydrator (Seno Iron Works Co., Ltd., Hokkaido, Japan). Residue was pressed using a screw press separator (PSS4-J, Nippon Engineering Corporation, Fukuoka, Japan) and the extract was added to the squeezed juice from the centrifugal dehydrator. The starch was separated from the squeezed juice by continuous centrifugal separation in a centrifugal separator (HS-324L, IHI Corporation, Tokyo, Japan). Proteins were collected from the supernatant, corresponding to the wastewater, by isoelectric focusing precipitation. The supernatant was adjusted to pH 4.5, and the precipitate was collected by centrifugation (LAPX 404SGP-31, Alfa Laval, Sweden). The precipitate (6.0 kg), including sweetpotato protein, was freeze dried and kept at −30 °C until use. One hundred and fifty grams of freeze dried precipitate was added to 15 L of pure water. The protein solution was digested with three proteases, Thermoase PC10F (Daiwa Kasei, Hyogo, Japan) (1.5 g), Protease S (Amano Enzyme, Aichi, Japan) (15 g), and Proleather FG-F (Amano Enzyme, Aichi, Japan) (15 g); these were selected because of their high protein degradation and ACE inhibitory activity. The protein solution was adjusted to pH 8.5, and the enzyme reaction was conducted at 65 °C for 16 h. The digest was then boiled for 30 min to inactivate the enzymes. The digest was filtered using activated carbon and spray-dried. The dried digest (SPP) was used in the animal experiments.

2.3. Animal experiments {#sec0025}
-----------------------

Animal experiments were performed by Skylight Biotech Inc. at Akita University (Akita, Japan). Mice were maintained at a room temperature of 23 ± 2 °C and relative humidity of 55 ± 5% under a 12 h light-dark cycle. Five-week-old male C57BL/6 mice (Japan SLC, Inc., Shizuoka, Japan) were fed High Fat Diet 32 (CLEA Japan, Inc., Tokyo, Japan) ([Table 1](#tbl0005){ref-type="table"}) and acclimatized for 1 week. Mice were divided into three groups consisting of five animals, according to body weight. The levels of serum cholesterol and triglyceride in mice were not significantly different between the three groups at the beginning of the experiment. The control group was fed High Fat Diet 32, and test groups were fed High Fat Diet 32 containing SPP at a concentration of 5% (w/w) or 0.5% (w/w). Food and sterile water were available *ad libitum*. All mice were assessed to be in good health throughout the experiments and no forms of toxicity were observed in mice administered SPP. Twenty eight days after initiation of the test diets, body weight was measured and blood samples for the measurement of cholesterol, triglyceride, leptin and adiponectin were obtained from the heart under ketamin anesthesia. The mice were fasted from 22:00 h the day before and sampling was conducted at 10:00 h. After blood sampling, liver, mesenteric fat and epididymal fat were isolated and weighed. Serum samples and livers were stored at −80 °C until use. The animals were treated according to the "Guidelines for Proper Conduct of Animal Experiments" (Science Council of Japan). The study was approved by the Ethics Committee of Akita University.

2.4. Measurements of serum cholesterol, triglyceride, leptin and adiponectin {#sec0030}
----------------------------------------------------------------------------

Total cholesterol, triglyceride, leptin and adiponectin were measured 28 days after the start of the experiment. Total cholesterol and triglyceride was measured using Cholestest CHO and Cholostest TG (Daiichi Pure Chemicals Co. Ltd., Tokyo, Japan), respectively. Serum leptin and adiponectin levels were measured using a Mouse Leptin ELISA Kit (Morinaga Institute of Biological Science, Yokohama, Japan) and a Mouse/Rat Adiponection ELISA Kit (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan), respectively.

2.5. Serum lipoprotein analysis by HPLC {#sec0035}
---------------------------------------

The cholesterol and triglyceride profiles in serum lipoproteins were analyzed by an online dual enzymatic method using HPLC with two tandem connected TSKgel LipopropakXL columns (300 × 7.8 mm; Tosho, Japan) at Skylight Biotech Inc. (Akita, Japan), according to the procedure described by [@bib0120]. The concentrations of cholesterol and triglyceride were determined in four fractioned groups according to lipoprotein particle size (diameter) ([Fig. 1](#fig0005){ref-type="fig"}), chylomicron (CM, \>80 nm), very low density lipoprotein (VLDL, 30--80 nm), low density lipoprotein (LDL, 16--30 nm), and high density lipoprotein (HDL, 8--16 nm), using enzymatic reagents (Kyowa Medex, Tokyo Japan). The concentrations of cholesterol and triglyceride were further analyzed in twenty sub-fractioned groups of CM (G01 and 02), VLDL (G03-05: large VLDL, G06: medium VLDL, G07: small VLDL), LDL (G08: large LDL, G09: medium LDL, G10: small LDL, G11-13: very small LDL) and HDL (G14, 15: very large HDL, G16: large HDL, G17: medium HDL, G18: small HDL, G19, 20: very small HDL).

2.6. Obesity peptide biomarker array analysis {#sec0040}
---------------------------------------------

The obesity peptide biomarker array analysis for mouse/rat (Phoenix Pharmaceuticals, Inc., CA, USA) was performed according to the manufacturer's instruction at Filgen Inc. (Nagoya, Japan). The liver tissues of a mouse selected from each group after 28 days administration of the high-fat diet containing SPP were isolated. The array consists of 44 different biomarkers: ACTH, adiponectin, ADM, AGRP, amylin, apelin-36, autotaxin, bombesin, CART, CCK, CGRP, CRF, desnutrin, dynorphin A, endorphin-beta, ghrelin, GHRF, GLP-1, GLP-2, glucagon, IL-6, IMD/AM-2, INSL-3, INSL-5, KISS-1, leptin, MCH, MSH-alpha, nesfatin, neuromedin U, NPB-29, NPW-23, NPY, orexin A, oxytocin, PACAP38, PrRP-31, PYY, RELM-beta, resistin, TNF-alpha, urocortin, VIP and visfatin. The expression levels of biomarkers in the liver of SPP-administered mice were compared to the control. The data was the average of two replications and the values are the ratio of the expression intensities of biomarkers derived from livers of 0.5% or 5% SPP administered mice to control mice.

2.7. Statistical analysis {#sec0045}
-------------------------

Statistical analyses of differences between the control group and the groups that received SPP were conducted using the multiple comparison test of Dunnet.

3. Results {#sec0050}
==========

3.1. Animal experiments {#sec0055}
-----------------------

Animal experiments were performed to assess the effect of SPP on body weight, abdominal adipose tissue mass, serum lipids and adipocytokines. The body weight of male C57BL/6 mice fed a high-fat diet containing 5% SPP was significantly lower than control mice, although food intake was not statistically different in all groups after 28 days administration ([Table 2](#tbl0010){ref-type="table"}). Liver weight and epididymal fat were significantly lower in the 0.5% (*P* \< 0.05) and 5% (*P* \< 0.01) SPP-administered groups compared with the control group ([Table 2](#tbl0010){ref-type="table"}). Mesenteric fat was significantly lower in the 5% (*P* \< 0.01) SPP-administered group compared with the control ([Table 2](#tbl0010){ref-type="table"}). Fatty liver was identified in control mice (moderately in 3 animals and slightly in 2 animals) and in 0.5% SPP-administered mice (moderately in 2 animals and slightly in 3 animals) according to the autopsy report. No mice in the 5% SPP-administered group were diagnosed with a fatty liver (data not shown).

Serum total cholesterol levels were not statistically different among any groups after 28 days administration of a high-fat diet containing SPP. The serum triglyceride levels were significantly lower in the 0.5% (*P* \< 0.05) and 5% (*P* \< 0.01) SPP-administered group compared with the control ([Table 3](#tbl0015){ref-type="table"}). There were no significant differences in serum adiponectin levels, while serum leptin levels were significantly lower in the 5% (*P* \< 0.01) SPP-administered group compared with the control ([Table 3](#tbl0015){ref-type="table"}). These results indicate that SPP prevents body weight gain, lipid accumulation in the fatty tissue and any elevations in serum triglyceride and leptin levels in mice fed a high-fat diet.

3.2. Cholesterol and triglyceride profiles in serum lipoproteins {#sec0060}
----------------------------------------------------------------

Cholesterol and triglyceride levels in serum lipoproteins, CM, VLDL, LDL and HDL, after 28 days administration of a high-fat diet containing SPP were analyzed by HPLC. Cholesterol levels were significantly lower in the SPP-administered group compared with the control in serum VLDL and LDL ([Fig. 1](#fig0005){ref-type="fig"}A). Triglyceride levels were also lower in the SPP-administered group compared with the control in serum VLDL, LDL and HDL ([Fig. 1](#fig0005){ref-type="fig"}B). Cholesterol and triglyceride profiles were further analyzed in 20 sub-fractioned groups of CM, VLDL, LDL and HDL. Cholesterol levels were lower in the serum of SPP-administered mice compared with the control mice in G04-G06 (large VLDL and medium VLDL), G11-15 (very small LDL and very large HDL) and G16-G18 (large, medium and small HDL) ([Fig. 2](#fig0010){ref-type="fig"}A). SPP dose-dependent responses in cholesterol levels were observed, in particular, in very small LDL (G11-13). Triglyceride levels were considerably lower in the serum of SPP-administered mice in fractions G03-G08 (large, medium and small VLDL and large LDL) ([Fig. 2](#fig0010){ref-type="fig"}B). These results indicate that the reductions in triglyceride and cholesterol levels by SPP was dependent on the particle size in serum lipoproteins.

3.3. Metabolic disease related biomarker array analysis {#sec0065}
-------------------------------------------------------

In order to evaluate the effect of SPP on factors related to metabolic diseases, biomarker array analysis was performed. Adrenocorticotrophic hormone (ACTH), adiponectin, KISS-1, melanocyte-stimulating-hormone-alpha (MSH-alpha), nesfatin, neuromedin U, neuropeptide W-23 (NPW-23), orexin A and resistin were more than 1.5 times higher in the liver of 0.5% and/or 5% SPP-administered mice compared to the control mice. TNF-alpha and desnutrin were about 1.5 times lower in the 0.5% or 5% SPP-administered mice compared to the control mice ([Table 4](#tbl0020){ref-type="table"}). These results suggest that SPP administration ameliorates the abnormality of secretion of some adipocytokines and neuropeptides related to appetite, and contributes to the control of lipid metabolism in mice fed a high-fat diet.

4. Discussion {#sec0070}
=============

Visceral adipose tissue accumulation is an important risk factor of metabolic and cardiovascular disorders ([@bib0010]). Increased low-density lipoprotein cholesterol (LDL-C) or decreased high-density lipoprotein cholesterol (HDL-C) and increased triglyceride are widely known risk factors of coronary heart disease (CHD) ([@bib0070]). A previous study showed that the visceral fat area positively correlated with very low-density lipoprotein cholesterol (VLDL-C) and LDL-C in 62 male subjects ([@bib0075]). In this study, we demonstrated that body weight gain, accumulation of visceral fat and fatty liver symptoms were suppressed in mice administered a SPP diet ([Table 2](#tbl0010){ref-type="table"}). Serum VLDL-C and LDL-C levels were significantly lower in SPP-administered mice compared to control mice ([Fig. 1](#fig0005){ref-type="fig"}A), although serum total cholesterol was not significantly different among the groups ([Table 3](#tbl0015){ref-type="table"}). Triglyceride, which is abundant in VLDL, was also clearly lower in SPP-administered groups compared with the control ([Fig. 1](#fig0005){ref-type="fig"}B). These results suggest an intriguing possibility that SPP has the potential to mitigate hyperlipidemia and obesity.

The profiles of 20 lipoprotein sub-fractions from the serum of mice fed a high-fat diet suggested SPP had a dose-dependent effect on cholesterol levels, especially in very small LDL (G11-13) ([Fig. 2](#fig0010){ref-type="fig"}A). The predominance of small, dense LDL has been accepted as an important cardiovascular risk factor ([@bib0045]; [@bib0110]) and characteristic of the dyslipidemic state seen in type 2 diabetes ([@bib0095]). A relationship between predominance of small, dense LDL particles, high triglyceride levels and low HDL-C concentrations and cardiovascular diseases have been reported ([@bib0005]; [@bib0015]; [@bib0075]). Our results suggest SPP may be advantageous in subjects with lipid abnormalities and heart disease by reducing the levels of VLDL-C, very small LDL-C and VLDL-triglyceride.

Lipid and sugar metabolism is maintained by various adipocytokines and neuropeptides related to food intake. Leptin is an anorexigenic adipocytokine, primarily secreted by adipocyte cells. Plasma leptin levels are elevated in subjects who are overweight, suggesting obesity may be associated with leptin resistance ([@bib0105]). Leptin also influences the activity of various orexigenic and anorexigenic peptides in the hypothalamus ([@bib0040]). Leptin resistance disrupts hypothalamic control of energy homeostasis, which results in obesity and increased lipid production ([@bib0125]). MSH-alpha decreases body fat in humans, regulates energy balance, appetite control and glucose transport in rat adipocytes ([@bib0060]). MSH-alpha, together with ACTH and endorphin-beta, are synthesized by proteolytic processing of the proopiomelanocortin (POMC) precursor in the pituitary and brain: POMC levels are increased by leptin ([@bib0125]). Neuromedin U is also a hypothalamic neuropeptide, that regulates body weight through the effects of anorexigenic activity and energy expenditure, independent of the leptin signaling pathway ([@bib0025]). Adiponectin plays an important role in metabolic regulation processes in various tissues: it suppresses gluconeogenesis, lipogenesis and triglyceride levels in the liver ([@bib0100]). TNF-alpha, a proinflammatory cytokine, is increased in the adipose tissue of obese mice and subjects ([@bib0085]). TNF-alpha reduces adiponectin expression and induces the overproduction of VLDL particles, which might explain its direct relationship with serum triglycerides ([@bib0090]). The secretion of TNF-alpha is stimulated by leptin ([@bib0125]). In our study, serum leptin levels were dose-dependently suppressed in SPP-administered mice after 28 days administration of a high-fat diet containing SPP ([Table 3](#tbl0015){ref-type="table"}). In addition, biomarkers associated with obesity and lipid abnormality were increased in the livers of SPP-administered mice, in particular, the levels of adiponectin, MSH-alpha and neuromedin U were more than 1.5 times higher in both the 0.5% and 5% SPP-administered groups compared with the control ([Table 4](#tbl0020){ref-type="table"}). TNF-alpha was about 1.5 times lower in the 5% SPP-administered group compared with the control group ([Table 4](#tbl0020){ref-type="table"}). These results suggest that SPP mitigated leptin resistance in mice administered a high-fat diet, and maintained anorexigenic peptide levels, such as MSH-alpha and neuromedin U. SPP administration may suppress lipogenesis and triglyceride levels by increasing adiponectin levels and decreasing TNF-alpha levels in adipocyte tissues.

There are many reports of enzyme digests derived from food protein with activities which potentially prevent lifestyle diseases: angiotensin I-converting enzyme inhibition ([@bib0115]; [@bib0020]; [@bib0130]), vasorelaxing activity ([@bib0135]), hypocholesterolemic activity ([@bib0135]; [@bib0055]; [@bib0050]), immunostimulating activity ([@bib0135]), antioxidation ([@bib0145]), amelioration of glucose tolerance ([@bib0080]) and inhibition of HIV protease ([@bib0140]). We report that SPP, derived from sweetpotato, might contribute to the amelioration of lipid abnormality and have identified four peptides, I-T-P, G-Q-Y, I-I-P and S-T-Y-Q-T, which may be responsible for the activity. Further research into the roles of these peptides are required.

5. Conclusion {#sec0075}
=============

SPP was prepared from sweetpotato starch wastewater using a combination of three proteases. SPP inhibited body weight gain, visceral fat gain and alleviation of fatty liver symptoms. In addition, SPP lowered the levels of triglyceride, very small LDL-C and VLDL-C in serum. The involvement of SPP in the regulation of expression of anorexigenic neuropeptides and adipocytokines was experimentally inferred. It is expected that SPP could be used as a functional food material for people with metabolic disorders. However, the administration level of SPP would be required for human health is uncertain at this study. Human intervention studies are needed for confirmation of the effect of SPP administration on the disorder of lipid metabolism.
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![Cholesterol (A) and triglyceride (B) concentrations in CM, VLDL, LDL and HDL in the serum of C57BL/6 mice fed a high-fat diet containing SPP for 28 days. Vertical bars represent the mean ± SD. Statistical significance of the difference in cholesterol and triglyceride between the control group and SPP-administered groups was evaluated using the Dunnet test (n = 5; \**p* \< 0.05, \*\**p* \< 0.01).](gr1){#fig0005}

![Cholesterol (A) and triglyceride (B) concentrations in 20 sub-fractionated groups of CM, VLDL, LDL and HDL in the serum of C57BL/6 mice fed a high-fat diet containing SPP for 28 days. Each sub-fractionated group was assigned to CM (G01 and 02), VLDL (G03-05: large VLDL, G06: medium VLDL, G07: small VLDL), LDL (G08: large LDL, G09: medium LDL, G10: small LDL, group G11-13: very small LDL) and HDL (G14, 15: very large HDL, G16: large HDL, G17: medium HDL, G18: small HDL, G19, 20: very small HDL), according to their particle size.](gr2){#fig0010}

###### 

Composition of the high-fat diet.

Table 1

  Ingredients                Composition (%)
  -------------------------- -----------------
  Milk Casein                24.5
  Egg Albumen powder         5.0
  L-cystine                  0.43
  Beef fat powder            15.88
  Safflower oil              20.0
  Crystalline cellulose      5.5
  Malto dextrin              8.25
  Lactose                    6.928
  Sucrose                    6.75
  AIN96 vitamin mixture      1.4
  AIN96 mineral mixture      5.0
  Choline bitartrate         0.36
  *tert*-butylhydroquinone   0.002

###### 

Body weight, food intake and adipose tissue weights of C57BL/6 mice fed a high-fat diet containing SPP for 28 days.

Table 2

                            Dietary groups                                     
  ------------------------- ---------------- ------ -------- ------ ---------- ------
  Initial body weight (g)   21.7             0.5    21.7     0.5    21.7       0.5
  Final body weight (g)     28.7             0.9    27.6     1.2    25.4\*\*   1.0
  Food intake (g)           69.1             4.3    74.1     19.3   72.7       8.3
  Liver weight (g)          1.06             0.03   0.99\*   0.03   0.92\*\*   0.06
  Mesenteric fat (g)        0.31             0.05   0.24     0.05   0.16\*\*   0.05
  Epididymal fat (g)        0.57             0.08   0.42\*   0.10   0.29\*\*   0.08

Values are means and standard deviations (SD) for five mice per group. Statistical significances of differences between control group and SPP-administered groups were evaluated using the Dunnet test (\**p* \< 0.05, \*\**p* \< 0.01).

###### 

Serum total cholesterol, triglyceride, adiponectin and leptin levels of C57BL/6 mice fed a high-fat diet containing SPP for 28 days.

Table 3

                              Dietary groups                                     
  --------------------------- ---------------- ------ -------- ------ ---------- ------
  Total cholesterol (mg/dL)   137.5            11.5   128.1    10.6   127.6      9.3
  Triglyceride (mg/dL)        78.2             12.0   51.5\*   17.4   45.5\*\*   11.9
  Adiponectin (μg/mL)         15.4             1.9    14.3     2.6    13.6       1.0
  Leptin (ng/mL)              9.4              2.9    7.0      3.8    2.8\*\*    2.0

Values are means and standard deviations (SD) for five mice per group. Statistical significances of differences between control group and SPP-administered groups were evaluated using the Dunnet test (\**p* \< 0.05, \*\**p* \< 0.01).

###### 

Changes in expression of obesity biomarkers in the liver of C57BL/6 mice fed a high-fat diet containing SPP.

Table 4

  Biomarkers       0.5% SPP   5% SPP     Biomarkers     0.5% SPP   5% SPP
  ---------------- ---------- ---------- -------------- ---------- ----------
  ACTH             1.568846   1.207352   INSL-3         1.247944   1.004722
  Adiponectin      1.869254   2.018212   INSL-5         1.128766   1.006280
  ADM              0.942962   0.996387   KISS-1         2.374750   1.311740
  AGRP             1.217677   1.201734   Leptin         1.213525   1.004622
  Amylin           1.222357   1.156575   MCH            1.284525   1.285361
  Apelin-36        1.198470   1.085409   MSH-alpha      2.260421   1.556036
  Autotaxin        1.073183   0.982489   Nesfatin       2.199554   1.381554
  Bombesin         1.221198   1.060198   Neuromedin U   2.305536   1.638912
  CART             1.070417   1.063943   NPB-29         1.198133   1.029302
  CCK              1.142432   1.033288   NPW-23         1.581845   1.153735
  CGRP             1.325779   1.167294   NPY            1.246320   1.073343
  CRF              1.077451   0.960503   Orexin A       2.120926   1.415045
  Desnutrin        0.460312   1.086319   Oxytocin       1.236405   0.917337
  Dynorphin A      1.110873   0.922335   PACAP38        1.290654   1.026850
  Endorphin-beta   1.311076   1.084468   PrRP-31        1.130610   1.020291
  Ghrelin          1.241355   1.112199   PYY            1.144237   0.981967
  GHRF             1.264400   1.145316   RELM-beta      1.152111   0.962001
  GLP-1            1.151995   1.069993   Resistin       2.731225   1.439922
  GLP-2            1.274524   1.363427   TNF-alpha      0.701973   0.589492
  Glucagon         1.190494   1.129924   Urocortin      1.188631   1.001872
  IL-6             1.129821   0.858137   VIP            0.828300   1.023039
  IMD/AM-2         1.343179   1.044383   Visfatin       1.197846   1.093286

Values are the ratio of the expression intensities of biomarkers derived from livers of 0.5% or 5% SPP administered mice to control mice.
